Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Oct 29, 2025.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.031g, Cetuximab (Erbitux®)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Oct 29, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.031g for Cetuximab (Erbitux®) has been reissued and updated. This is a fresh pharmacy policy change that may affect coverage, prior authorization, or billing requirements for this oncology medication.

Action Required

Action needed

By October 29, 2025: Billing team should review the updated MA08.031g policy for Cetuximab (Erbitux®) to understand any changes to coverage criteria, prior authorization requirements, or billing procedures. Access the full policy details at the provided URL to determine specific workflow updates needed for Medicare Advantage patients receiving this oncology medication.

Related policy hubs

Independence Blue Cross policies Oncology Hematology